Market Newsdesk

April 3, 2025 1:09 pm

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Monolithic Power Systems Inc. (MPWR) Shareholders

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Monolithic Power Systems Inc. (NASDAQ: MPWR).

Shareholders who purchased shares of MPWR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

https://securitiesclasslaw.com/securities/monolithic-loss-submission-form/?id=140423&from=3

CLASS PERIOD: February 8, 2024 to November 8, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) Monolithic’s voltage regulator modules and power management integrated circuits were suffering from significant performance and quality control issues; (b) the defects listed in (a), above, had, in turn, negatively impacted the performance of certain products offered by the Company’s largest customer, Nvidia, in which such products were used; (c) Monolithic had failed to adequately address and resolve known issues affecting the performance of the power management solutions the Company supplied to Nvidia; (d) Monolithic’s relationship with Nvidia had been irreparably damaged due to the significant performance and quality control.

DEADLINE: April 7, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/monolithic-loss-submission-form/?id=140423&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MPWR during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 7, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

April 3, 2025 1:09 pm

Skyworks Solutions, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SWKS

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Skyworks Solutions, Inc. (NASDAQ: SWKS).

Shareholders who purchased shares of SWKS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

https://securitiesclasslaw.com/securities/skyworks-solutions-inc-loss-submission-form/?id=140427&from=3

CLASS PERIOD: July 30, 2024 to February 5, 2025

ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Skyworks’ expected revenue for the fiscal year 2025. Defendants’ statements included, among other things, confidence in Skyworks’ ability to expand its mobile business and capitalize on its growth potential by investing in new technologies to diversify its portfolio of offerings. On February 5, 2025, after market close, Skyworks announced its financial results for the first quarter of fiscal year 2025 and provided lower-than anticipated revenue guidance for the second quarter of fiscal year 2025. The Company attributed its results and low guidance to a “competitive landscape” that had “intensified” in recent years. Following this news, the price of Skyworks’ common stock declined dramatically. From a closing market price of $87.08 per share on February 5, 2025, Skyworks’ stock price fell to $65.60 per share on February 6, 2025, a decline of over 24% in the span of just a single day.

DEADLINE: May 5, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/skyworks-solutions-inc-loss-submission-form/?id=140427&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SWKS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 5, 2025. There is no cost or obligation to you to participate in this case.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

April 3, 2025 1:09 pm

Shareholders that lost money on e.l.f. Beauty, Inc. (ELF) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of e.l.f. Beauty, Inc. (NYSE: ELF).

Shareholders who purchased shares of ELF during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

https://securitiesclasslaw.com/securities/e-l-f-beauty-loss-submission-form/?id=140424&from=3

CLASS PERIOD: November 1, 2023 to November 19, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) contrary to its representations to investors, the Company was experiencing rising inventory levels as a consequence of flagging sales; (ii) Elf falsely attributed the rising inventory levels to, among other things, changes in its sourcing practices; (iii) to maintain investor confidence, Elf reported inflated revenue, profits, and inventory over several quarters; (iv) the Company’s business and/or financial prospects were overstated; (v) all of the foregoing, once revealed, would likely have a material negative impact on the Company; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

DEADLINE: May 5, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/e-l-f-beauty-loss-submission-form/?id=140424&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ELF during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 5, 2025. There is no cost or obligation to you to participate in this case.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

April 3, 2025 1:08 pm

Shareholders of Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – NMRA

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).

Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=140421&from=3

CLASS PERIOD: This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023.

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn’s original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora’s flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NMRA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 7, 2025. There is no cost or obligation to you to participate in this case.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

April 3, 2025 1:08 pm

Shareholders of Merck & Co., Inc. Should Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights – MRK

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).

Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=140422&from=3

CLASS PERIOD: February 3, 2022 to February 3, 2025

ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Merck’s expected revenue of $11 billion from sales of Gardasil by 2030. Defendants’ statements included, among other things, confidence in Merck’s purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in order to drive demand and capitalize on eligible populations for vaccination, resulting in confidently optimistic reports and forecasts of Gardasil’s growth in China. The full truth finally emerged on February 4, 2025, when Merck announced it would no longer achieve the long-forecasted $11 billion in sales of Gardasil by 2030, as it would cease shipments of Gardasil to China “through at least midyear” to facilitate a “rapid reduction of inventory.” Defendants claimed this was necessitated by the continued over-inflation of overall channel inventories as demand in China for Gardasil had “not recovered to the level we had expected.” Following this news, Merck’s common stock declined dramatically. From a closing market price of $99.79 per share on February 3, 2025, Merck’s stock price fell to $90.74 per share on February 4, 2025, a decline of more than 9% in the span of just a single day.

DEADLINE: April 14, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=140422&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MRK during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 14, 2025. There is no cost or obligation to you to participate in this case.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

April 3, 2025 1:07 pm

TMDX LAWSUIT ALERT: The Gross Law Firm Notifies TransMedics Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).

Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=140419&from=3

CLASS PERIOD: February 28, 2023 to January 10, 2025

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

DEADLINE: April 15, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=140419&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of TMDX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 15, 2025. There is no cost or obligation to you to participate in this case.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

April 3, 2025 1:07 pm

April 28, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against QUBT

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Quantum Computing Inc. (NASDAQ: QUBT).

Shareholders who purchased shares of QUBT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

https://securitiesclasslaw.com/securities/quantum-computing-inc-loss-submission-form/?id=140420&from=3

CLASS PERIOD: March 30, 2020 to January 15, 2025

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) defendants overstated the capabilities of QCI’s quantum computing technologies, products, and/or services; (ii) defendants overstated the scope and nature of QCI’s relationship with NASA, as well as the scope and nature of QCI’s NASA-related contracts and/or subcontracts; (iii) defendants overstated QCI’s progress in developing a thin film lithium niobate, TFLN foundry, the scale of the purported TFLN foundry, and orders for the Company’s TFLN chips; (iv) QCI’s business dealings with Quad M and millionways both qualified as related party transactions; (v) accordingly, QCI’s revenues relied, at least in part, on undisclosed related party transactions; (vi) all the foregoing, once revealed, was likely to have a significant negative impact on QCI’s business and reputation; and (vii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

DEADLINE: April 28, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/quantum-computing-inc-loss-submission-form/?id=140420&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of QUBT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 28, 2025. There is no cost or obligation to you to participate in this case.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

April 3, 2025 1:06 pm

CONSUMERS CAN NOW BUILD AND BUY THEIR DREAM E-Z-GO® VEHICLE FROM THE COMFORT OF HOME

PR Newswire

“Reserve Now” program allows buyers to customize and order a new E-Z-GO vehicle without going to a dealership

AUGUSTA, Ga.
, April 3, 2025 /PRNewswire/ — Textron E-Z-GO LLC, a Textron Inc. (NYSE: TXT) company, announces its new “Reserve Now” feature to enable anyone to customize and order their dream E-Z-GO^®golf car, personal-transport vehicle, or street-legal low-speed vehicles online, without an initial visit to a dealership.

This new feature helps future E-Z-GO owners save time and energy and allows them to craft the E-Z-GO vehicle they want, with multiple color, seating, lighting, and accessory options to fit their needs. E-Z-GO, a Textron Specialized Vehicles business, designs and manufactures E-Z-GO vehicles in Augusta, Ga.

“At E-Z-GO, we want to make the process of buying a golf car as easy and fun as our vehicles are to drive,” said Rob Scholl, president and CEO of Textron Specialized Vehicles Inc. “Today’s consumers expect to be able to order the products they want and need online, and we’re proud to give them that ability.”

The “Reserve Now” process is simple. Buyers visit the E-Z-GO website at ezgo.com, use the online “vehicle builder” to customize the model of their choice, and place a $500 deposit online. The vehicle will be built to the customer’s order and delivered to their nearest Authorized E-Z-GO Dealer for final preparation, payment and pickup by the customer. Most orders will be filled within eight weeks; some models and option packages may require longer lead times. Customers also can search nearby dealer inventories for a vehicle that suits their needs and request a quote online for new and used vehicles already in stock.

Customers can use the “Reserve Now” feature to customize and order E-Z-GO Freedom^®, Liberty, street-legal Liberty LSV, Express^®and Valor^®models. Throughout 2025, E-Z-GO will release new special-edition vehicles in new eye-catching colors and decked out with special features, such as the new Phantom limited edition – a pure-white Freedom RXV with black premium seats, a modular top, tinted windshield, LED lights, premium steering wheel, soundbar and the IntelliGauge™ smart gauge system.

For more information about E-Z-GO, the “Reserve Now” program, and the complete line of E-Z-GO vehicles, visit ezgo.com.

About E-Z-GO

Founded in Augusta, Ga. in 1954, E-Z-GO is a globally renowned leader in the design and manufacture of golf cars and personal transport vehicles, known for its use of innovative sustainable electric-vehicle and powertrain technology. E-Z-GO models include RXV^®fleet golf cars; Freedom^®and Valor personal golf cars, and E-Z-GO Express™ personal utility vehicles. Its latest innovation is the Liberty™, the industry’s first vehicle to offer four forward-facing seats in a compact, golf-car-sized footprint. E-Z-GO became part of Textron Inc. (NYSE: TXT) in 1960, and today operates as a Textron Specialized Vehicles business of Textron Inc.

About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, Arctic Cat, and Textron Systems. For more information, visit: www.textron.com.

Certain statements in this press release may project revenues or describe strategies, goals, outlooks or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements.

Contact:

Joe Spencer

816-824-3416

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/consumers-can-now-build-and-buy-their-dream-e-z-go-vehicle-from-the-comfort-of-home-302420130.html

SOURCE E-Z-GO

April 3, 2025 1:06 pm

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).

Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=140417&from=3

CLASS PERIOD: July 30, 2024 to January 8, 2025

ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Intellia’s Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants’ statements included, among other things, confidence in the Company’s timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific research community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain. The truth emerged on January 9, 2025, when Intellia published a press release announcing Company reorganization. In pertinent part, defendants disclosed that Intellia would be halting all NTLA-3001 research and studies and that the Company would be reducing its workforce by 27% in 2025. Specifically, the Company announced that management decided to focus Intellia’s resources on other pharmaceutical development and would be implementing cost saving in the form of a major reduction in force. As a result, defendants pipeline priority readjustment resulted in the Company’s once-touted NTLA-3001’s discontinuation. Following this news, Intellia’s stock price fell from a closing market price of $12.02 per share on January 8, 2025 to $10.20 per share on January 10, 2025.

DEADLINE: April 14, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=140417&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NTLA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 14, 2025. There is no cost or obligation to you to participate in this case.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

April 3, 2025 1:06 pm

Shareholders that lost money on ICON Public Limited Company (ICLR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company (NASDAQ: ICLR).

Shareholders who purchased shares of ICLR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

https://securitiesclasslaw.com/securities/icon-public-limited-company-loss-submission-form/?id=140416&from=3

CLASS PERIOD: July 27, 2023 to October 23, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a)ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting the Company’s client base; (b)ICON’s purported functional service provision and hybrid model offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (d)ICON’s customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (e)ICON’s two largest customers were diversifying their clinical research organization providers away from the Company; (f)as a result of (a)-(e) above, ICON’s reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON’s services; and (g)as a result of (a)-(f) above, ICON was tracking materially below the 2024 revenue and EPS guidance issued during the Class Period and such guidance lacked a reasonable factual basis.

DEADLINE: April 11, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/icon-public-limited-company-loss-submission-form/?id=140416&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ICLR during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 11, 2025. There is no cost or obligation to you to participate in this case.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903